Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 21, 2023

Real-World Evidence for Efficacy and Safety of Durvalumab Consolidation After Chemoradiotherapy in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR
J Thorac Oncol 2023 Apr 19;[EPub Ahead of Print], CK Park, HJ Oh, YC Kim, YH Kim, SJ Ahn, WG Jeong, JY Lee, JC Lee, CM Choi, W Ji, SY Song, J Choi, SY Lee, H Kim, SY Lee, J Park, SH Yoon, JH Joo, IJ Oh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading